Frederick Lundry Locke MD

Oncology•Tampa, FL

Hematologic Oncology

Senior Member and Chair Department of Blood and Marrow Transplant and Cellular Immunotherapy and Co-Leader, Immunology Program Moffitt Cancer Center

Request appointment

12902 Usf Magnolia DrTampa, FL 33612
Book by Phone+1(218) 423-4396
Fax+1 813-745-8468

Overview of Dr. Locke

Dr. Frederick Locke is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Wayne State University School of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, non-hodgkin's lymphoma, immunology, and chimeric antigen receptor (CAR) t-cell therapy.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
Wayne State University School of MedicineResidency, Internal Medicine, 2002 - 2006
Wayne State University School of MedicineClass of 2002

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2010 - 2027
IL State Medical License 2006 - 2011
MI State Medical License 2002 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2016-2017
CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2016-2017

Clinical Trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
COMPLETED
PHASE2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
COMPLETED
PHASE1, PHASE2
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
COMPLETED
PHASE2

Publications & Presentations

PubMed

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.
Joseph A Pidala, Jongphil Kim, Jose Laborde, Samantha Knott, Krishnakar Mogili
Blood Advances. 2026-07-21
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.
Aditi Saha, Junmin Whiting, Razan Mohty, Kristen Flores, Jongphil Kim
Bone Marrow Transplantation. 2026-07-17
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.
Hitomi Hosoya, Arash Velayati, Danai Dima, Alexandria Jensen, Andrew J Portuguese
Blood. 2026-07-08

Abstracts/Posters

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

15 Leaders Challenge Oversimplified View of ImmunotherapyJanuary 30th, 2026
Phase 3 Study Results Show Metabolic Tumor Volume Improves Prognosis Compared to SPD in Second-Line R/R LBCLDecember 11th, 2022
$Body of Evidence Grows from ZUMA-7 Study Supporting Initial Treatment with Kite’s Yescarta® CAR T-cell Therapy for Patients with Relapsed or Refractory Large B-cell Lymphoma$
Body of Evidence Grows from ZUMA-7 Study Supporting Initial Treatment with Kite’s Yescarta® CAR T-cell Therapy for Patients with Relapsed or Refractory Large B-cell LymphomaDecember 11th, 2022

Grant Support

Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled ComparisonH. LEE MOFFITT CANCER CTR & RES INST2022–2027

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
Society for Immunotherapy of Cancer
Member
American Society of Blood and Marrow Transplantation - ASBMT
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PPO
Network Health Plan HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment